Tuesday April 20, 2021 0 comments
DENVER --VieCure, Inc. today announced the closing of a $25 million Series A growth equity investment, led by Northpond Ventures.
An undisclosed investor is also contributing to the round. VieCure, an oncology clinical informatics company with an artificial intelligence (AI) enabled clinical decision support platform, will use the new funding to accelerate the deployment of its next generation clinical decision support solution, and grow the sales and business development organization in response to the expanding pipeline and partnering opportunities in the life sciences arena.
Andrea Jackson, director for Northpond Ventures, will join the new VieCure board of directors.
The VieCure platform is a real-time clinical decision support system that combines the latest in evidence and clinical trials with patient data to assist surgical oncologists, medical oncologists, radiation oncologists, hematologists, and clinical trial investigators in generating personalized treatment plans, as well as managing a patient's treatment throughout diagnosis, cancer therapy, and ongoing follow-up care.
VieCure is contracted with cancer centers and health systems in the United States, Bahamas, and Antigua, and has forged meaningful strategic alliances with global pharmaceutical, molecular diagnostic, and laboratory companies.
The VieCure platform becomes the core operating system for a cancer center or cancer care network. This includes codified clinical and payor content, the smart “EMR” in oncology, the artificial intelligence inference engine, a tethered patient mobile app, an integrated teleoncology solution, and the most robust analytics functionality that facilitates immediate access to meaningful and curated datasets.
“Northpond Ventures is excited to support VieCure and its expanding presence in the U.S. and global cancer care market,” said Jackson.
“The VieCure platform is an ideal operating solution for oncologists, nurses, pharmacists, and clinical trial professionals, given it is designed for the precision oncology era and supports clinical decision making at point-of-care.
“The precision oncology paradigm shift is underway and the amount of data that clinicians are being expected to digest, consider, and action is often beyond the human condition.
“The VieCure platform ingests these data discretely, inferences these data against the latest clinical evidence and trial protocols, and generates optimal treatment plan considerations for action while the patient is in the exam room.
“We are excited to be an investor in and collaborator with VieCure. I’m looking forward to working with the leadership team and new Board to advance their mission to improve outcomes for people with cancer.”
VieCure, based in Denver, has executed multi-year agreements with several cancer centers in the U.S., such as with Alabama Cancer Care (10 cancer center locations throughout Alabama) and The Center for Cancer and Blood Disorders (nine cancer center locations in Texas).
“We are very pleased to have Northpond Ventures as a member of our team,” said Gerry Hogue, president and CEO of VieCure.
“We are in business for two reasons and two reasons only: to help clinicians with day-to-day decision making responsibilities and to facilitate improved clinical outcomes for patients. We launched VieCure to help oncologists and patients in community oncology settings as they embrace the best of clinical evidence and to assist them with their accelerated adoption of precision oncology.
“Over 70% of cancer patients are treated in private practice cancer centers and community hospitals. These professionals see and treat the bulk of cancer patients in the U.S. and the demands on their time are only increasing.
“The VieCure platform ensures they can offer the latest in clinical evidence and trials and be compliant with the latest payor rules, value based care programs, center-specific drug formulary, and related oncology supply contracts.
“Additionally, our platform is designed to facilitate optimal and timely decision making, which results in improved fiscal performance for the cancer center or health system.”